Table 3.
Comparison between the steroid exacerbated and non-exacerbated myasthenia gravis groups between our series and Bae et al. series.
| Our series | Bae et al. | |||
|---|---|---|---|---|
| Exacerbated (n = 1) | Non-exacerbated (n = 44) | Exacerbated (n = 23) | Non-exacerbated (n = 32) | |
| Demographic features | ||||
| Age (years) | 56 | 66.43 ± 16.38 | 52.3 ± 13.4 | 41.1 ± 15.4 |
| Male/female ratio | 1 | 29/15 | 8/15 | 12/20 |
| Age at onset (years) | 56 | 65.22 ± 16.32 | 48.5 ± 14.0 | 39.8 ± 15.4 |
| Pre-treatment clinical status of MG | ||||
| Pre-treatment dose of piridostigmine (mg) | 240 | 152.14 ± 94.96 | 259.8 ± 131.9 | 215.6 ± 115.1 |
| MSS score | 12 | 12.66 ± 1.66 | 9.4 ± 2.0 | 12.5 ± 1.6 |
| Functional MG scale score | 4 | 3.22 ± 0.82 | 4.4 ± 0.6 | 3.4 ± 0.6 |
| Thymomatous MG (n) | 0 | 2 | 8 | 14 |
| Thymectomized MG (n) | 0 | 15 | 13 | 17 |
| Laboratory findings | ||||
| Patients with AChR-Ab (%) | 1 | 90.9% | – | – |
| Outcome after use of PDN | ||||
| Reason for PDN use, bulbar symtoms (n) | 1 | 29 | 23 | 18 |
| Total PDN dose | 100 | 62.5 ± 15.87 | 66.7 ± 11.6 | 62.3 ± 14.5 |
| Dose per body weight (mg/kg) | 1 | 0.9 ± 0.15 | 1.3 ± 0.3 | 1.1 ± 0.4 |
| Non-responders (within 6 weeks) | 0 | 1 | 5 | 16 |